news
UCB receives EU approval for paediatric anti-epileptic drug
UCB has announced that the EC has approved the use of its anti-epileptic drug Vimpatas in the treatment of partial-onset seizures...
List view / Grid view
UCB
news
UCB and Amgen’s Osteoporosis study shows bone mineral density gains
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The BRIDGE study involved 245 men with osteoporosis randomised 2:1 to receive either 210 mg romosozumab or placebo subcutaneously once monthly for 1 year...
news
UCB and Amgen submit FDA application for Osteoporosis drug
22 July 2016 | By Niamh Louise Marriott, Digital Content Producer
UCB and Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for romosozumab, an investigational, monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture...
news
NICE recommends certolizumab pegol in draft guidance
12 July 2016 | By Victoria White, Digital Content Producer
Certolizumab pegol is recommended as an option for people with severe rheumatoid arthritis when other drugs haven’t worked or aren’t suitable...
news
SMC accepts five new medicines for use in NHS Scotland
11 July 2016 | By Victoria White, Digital Content Producer
The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib...
news
Bimekizumab demonstrates positive results in patients with psoriatic arthritis
10 June 2016 | By Victoria White, Digital Content Producer
In a Phase Ib study, bimekizumab showed fast and sustained efficacy on disease activity measures in both skin and joints and was well-tolerated...
news
Positive top-line results from Phase III study of romosozumab in osteoporosis
21 March 2016 | By Victoria White
The study demonstrated a statistically significant increase in bone mineral density at the lumbar spine in men with osteoporosis treated with romosozumab...
news
Brivaracetam launches in the UK as a new option for patients with uncontrolled epilepsy
29 February 2016 | By Victoria White
UCB’s Briviact (brivaracetam) has been authorised in the UK as an add-on treatment for partial onset seizures with or without secondary generalised seizures...
news
Positive top-line results for romosozumab FRAME study
23 February 2016 | By Victoria White
The Phase III FRAME study evaluated UCB and Amgen's romosozumab in postmenopausal women with osteoporosis...
news
NICE recommends 7 DMARDs for severe rheumatoid arthritis
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
news
Lannett completes acquisition of Kremers Urban Pharmaceuticals
27 November 2015 | By Victoria White
Lannett has acquired KU from UCB for a total consideration of approximately US$1.23 billion...
news
UCB to sell Kremers Urban to Lannett
3 September 2015 | By Victoria White
Lannett Company has entered into a definitive agreement to acquire UCB’s US generics subsidiary, Kremers Urban Pharmaceuticals, for $1.23 billion...
news
Positive results from Phase 3 study evaluating Cimzia in DMARD-naïve rheumatoid arthritis patients
15 June 2015 | By Victoria White
UCB has announced data from a Phase 3 study that showed the substantial benefits, at 52 weeks, of adding Cimzia to optimised methotrexate treatment...
news
UCB to focus on core business in India
1 April 2015 | By Victoria White
UCB has announced it has entered an agreement with Dr. Reddy’s to sell its established brands in India, allowing it to focus on its neurology portfolio...
news
UCB secures multi-million pound funding boost from UK Government
UCB has announced that its joint bid with five other UK-based organisations has been selected as a recipient of the Government’s 2014 Advanced Manufacturing Supply Chain Initiative (AMSCI), which will result in a £6.2 million grant to support the development of novel biologic treatments.
